Laboratory testing in the era of direct or non-vitamin k antagonist oral anticoagulants: A practical guide to measuring their activity and avoiding diagnostic errors

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 2, 2015, Pages 208-227

  Favaloro, Emmanuel J ^a   Lippi, Giuseppe ^b  

^a NSW Health Pathology   (Australia)

^b ACADEMIC HOSPITAL OF PARMA   (Italy)

Author keywords

apixaban; dabigatran; edoxaban; interference; measurement; NOACs; rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BETRIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ASSAY INTERFERENCE; BLOOD ANALYSIS; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DIAGNOSTIC ERROR; DILUTE RUSSELL VIPER VENOM TIME; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LIQUID CHROMATOGRAPHY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; POINT OF CARE TESTING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN TIME; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SCREENING TEST; TANDEM MASS SPECTROMETRY; THROMBIN TIME; URINALYSIS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG MONITORING; ORAL DRUG ADMINISTRATION; PREVENTION AND CONTROL; PROCEDURES;

ADMINISTRATION, ORAL; DIAGNOSTIC ERRORS; DRUG MONITORING; FACTOR XA INHIBITORS; HEMOSTASIS; HUMANS; VITAMIN K;

EID: 84923883820     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1546827     Document Type: Review

References (119)

1. Guyatt G. H., Akl E. A., Crowther M., Gutterman D. D., Schuünemann H. J.; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 2 Suppl 7S 47S
2. Lippi G., Franchini M., Favaloro E. J. Pharmacogenetics of vitamin K antagonists: useful or hype? Clin Chem Lab Med: 2009; 47 5 503 515
3. Favaloro E. J., Lippi G., Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology: 2011; 43 7 682 692
4. Lippi G., Favaloro E. J. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clin Chem Lab Med: 2015; 53 2 185 197
5. Husted S., de Caterina R., Andreotti F., et al. ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost: 2014; 111 5 781 782
6. Ruff C. T., Giugliano R. P., Braunwald E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet: 2014; 383 9921 955 962
7. McMahon B. J., Kwaan H. C. The new or non-vitamin K antagonist oral anticoagulants: what have we learned since their debut. Semin Thromb Hemost: 2015; 41 2 188 194
8. Favaloro E. J., Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med (Zagreb): 2012; 22 3 329 341
9. Harenberg J., Du S., Krämer S., Weiss C., Krämer R., Wehling M. Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants. Semin Thromb Hemost: 2015; 41 2 228 236
10. Zolfaghari S., Harenberg J., Frölich L., et al. Development of recommendations to continue anticoagulation with one of the two types of oral anticoagulants based on the identification of patients' preference. Semin Thromb Hemost: 2015; 41 2 166 177
11. van der Hulle T., Kooiman J., den Exter P. L., Dekkers O. M., Klok F. A., Huisman M. V. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost: 2014; 12 3 320 328
12. Loke Y. K., Pradhan S., Yeong J. K., Kwok C. S. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol: 2014; 78 4 707 717
13. Lippi G., Favaloro E. J., Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? Semin Thromb Hemost: 2014; 40 7 756 765
14. Gous T., Couchman L., Patel J. P., Paradzai C., Arya R., Flanagan R. J. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit: 2014; 36 5 597 605
15. Stangier J., Rathgen K., Stähle H., Gansser D., Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol: 2007; 64 3 292 303
16. Stangier J., Stähle H., Rathgen K., Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet: 2008; 47 1 47 59
17. van Ryn J., Stangier J., Haertter S., et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost: 2010; 103 6 1116 1127
18. Lindahl T. L., Baghaei F., Blixter I. F., et al. Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost: 2011; 105 2 371 378
19. Freyburger G., Macouillard G., Labrouche S., Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res: 2011; 127 5 457 465
20. Harenberg J., Giese C., Marx S., Krämer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost: 2012; 38 1 16 22
21. Douxfils J., Mullier F., Robert S., Chatelain C., Chatelain B., Dogné J. M. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost: 2012; 107 5 985 997
22. Halbmayer W. M., Weigel G., Quehenberger P., et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med: 2012; 50 9 1601 1605
23. Dager W. E., Gosselin R. C., Kitchen S., Dwyre D. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother: 2012; 46 12 1627 1636
24. Samama M. M., Guinet C., Le Flem L., Ninin E., Debue J. M. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis: 2013; 35 2 140 146
25. Helin T. A., Pakkanen A., Lassila R., Joutsi-Korhonen L. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem: 2013; 59 5 807 814
26. Hawes E. M., Deal A. M., Funk-Adcock D., et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost: 2013; 11 8 1493 1502
27. Douxfils J., Dogné J. M., Mullier F., et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost: 2013; 110 3 543 549
28. Hapgood G., Butler J., Malan E., Chunilal S., Tran H. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost: 2013; 110 2 308 315
29. Antovic J. P., Skeppholm M., Eintrei J., et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol: 2013; 69 11 1875 1881
30. Herrmann R., Thom J., Wood A., Phillips M., Muhammad S., Baker R. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost: 2014; 111 5 989 995
31. Eller T., Busse J., Dittrich M., et al. Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests. Clin Chem Lab Med: 2014; 52 6 835 844
32. Chin P. K., Wright D. F., Patterson D. M., Doogue M. P., Begg E. J. A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol: 2014; 78 3 599 609
33. Stang L., Nahirniak S., Butcher K., Szkotak A. J. Dabigatran assessment in patients with acute complications using routine coagulation assays. Blood Coagul Fibrinolysis: 2014; 25 5 426 434
34. Lind S. E., Boyle M. E., Fisher S., Ishimoto J., Trujillo T. C., Kiser T. H. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples. Am J Clin Pathol: 2014; 141 5 665 674
35. Schmitz E. M., Boonen K., van den Heuvel D. J., et al. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost: 2014; 12 10 1636 1646
36. van Ryn J., Grottke O., Spronk H. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays. Clin Lab Med: 2014; 34 3 479 501
37. Skeppholm M., Hjemdahl P., Antovic J. P., et al. On the monitoring of dabigatran treatment in real life patients with atrial fibrillation. Thromb Res: 2014; 134 4 783 789
38. Czubek U., Góralczyk T., Zalewski J., Undas A. Monitoring of anticoagulant effects of dabigatran in everyday practice: first experience in 32 Polish patients. Pol Arch Med Wewn: 2014; 124 9 487 489
39. Van Blerk M., Bailleul E., Chatelain B., et al. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost: 2015; 113 1 154 164
40. Martinuzzo M. E., Barrera L. H., D'adamo M. A., Otaso J. C., Gimenez M. I., Oyhamburu J. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol: 2014; 36 144 150
41. Bonar R., Favaloro E. J., Marsden K.; RCPAQAP Haematology Haemostasis Committee. Dabigatran Special Exercise Report. Issued April, 2014. RCPA Quality Assurance Programs Pty Limited. St Leonards, NSW, Australia
42. Stangier J., Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis: 2012; 23 2 138 143
43. Avecilla S. T., Ferrell C., Chandler W. L., Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol: 2012; 137 4 572 574
44. Samoš M., Stančiaková L., Ivanková J., et al. Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation. J Thromb Thrombolysis: 2015; 39 1 95 100
45. Visino F., Zaccaria F., Semeraro N., Colucci M. A modified prothrombin time to measure the anticoagulant activity of dabigatran. Thromb Res: 2014; 134 6 1368 1369
46. Gosselin R., Hawes E., Moll S., Adcock D. Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses: a prospective study based on peak and trough plasma levels. Am J Clin Pathol: 2014; 141 2 262 267
47. Gosselin R. C., Dwyre D. M., Dager W. E. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother: 2013; 47 12 1635 1640
48. Tsutsumi Y., Shimono J., Ohhigashi H., Ito S., Shiratori S., Teshima T. Analysis of the influence of dabigatran on coagulation factors and inhibitors. Int J Lab Hematol: 2014;; doi: 10.1111/ijlh.12270
49. Exner T., Ellwood L., Rubie J., Barancewicz A. Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study. Thromb Haemost: 2013; 109 4 762 765
50. Khoo T. L., Weatherburn C., Kershaw G., Reddel C. J., Curnow J., Dunkley S. The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol: 2013; 35 2 222 224
51. Solbeck S., Meyer M. A., Johansson P. I., et al. Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography. Int J Cardiol: 2014; 176 3 794 799
52. Xu Y., Wu W., Wang L., et al. Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro. Blood Coagul Fibrinolysis: 2013; 24 3 332 338
53. Hosokawa K., Ohnishi T., Sameshima H., et al. Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model. PLoS ONE: 2014; 9 1 e86491
54. Dale B. J., Ginsberg J. S., Johnston M., Hirsh J., Weitz J. I., Eikelboom J. W. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents. J Thromb Haemost: 2014; 12 11 1810 1815
55. Bonar R., Favaloro E. J., Marsden K.; RCPAQAP Haematology Haemostasis Committee. Apixaban and Rivaroxaban Trial Report. Issued December, 2014. RCPA Quality Assurance Programs Pty Limited. St Leonards, NSW, Australia
56. Samama M. M., Martinoli J. L., LeFlem L., et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost: 2010; 103 4 815 825
57. Francart S. J., Hawes E. M., Deal A. M., et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost: 2014; 111 6 1133 1140
58. Arachchillage D. R., Efthymiou M., Lawrie A. S., Machin S. J., Mackie I. J., Cohen H. Comparative sensitivity of commonly used thromboplastins to ex vivo therapeutic rivaroxaban levels. Thromb Haemost: 2014; 112 2 421 423
59. Tripodi A., Chantarangkul V., Guinet C., Samama M. M. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost: 2011; 9 1 226 228
60. Hillarp A., Baghaei F., Fagerberg Blixter I., et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost: 2011; 9 1 133 139
61. Douxfils J., Mullier F., Loosen C., Chatelain C., Chatelain B., Dogné J. M. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res: 2012; 130 6 956 966
62. Linkins L. A., Moffat K. Monitoring the anticoagulant effect after a massive rivaroxaban overdose. J Thromb Haemost: 2014; 12 9 1570 1571
63. Altman R., Gonzalez C. D. Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs. Thromb J: 2014; 12 1 7
64. Asmis L. M., Alberio L., Angelillo-Scherrer A., et al. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res: 2012; 129 4 492 498
65. Attard C., Monagle P., Kubitza D., Ignjatovic V. The in vitro anticoagulant effect of rivaroxaban in children. Thromb Res: 2012; 130 5 804 807
66. Harenberg J., Marx S., Krämer R., Giese C., Weiss C. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis: 2011; 22 8 637 641
67. Samama M. M., Contant G., Spiro T. E., et al. Rivaroxaban Prothrombin Time Field Trial Laboratories. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost: 2012; 18 2 150 158
68. Molenaar P. J., Dinkelaar J., Leyte A. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med: 2012; 50 10 1799 1807
69. Harenberg J., Erdle S., Marx S., Krämer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost: 2012; 38 2 178 184
70. Harder S., Parisius J., Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res: 2008; 123 2 396 403
71. Kluft C., Meijer P., Kret R., Burggraaf J. Preincubation in the Prothrombinase-induced Clotting Time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban. Int J Lab Hematol: 2013; 35 4 379 384
72. Gerotziafas G. T., Baccouche H., Sassi M., et al. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. Thromb Res: 2012; 129 1 101 103
73. Merriman E., Kaplan Z., Butler J., Malan E., Gan E., Tran H. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost: 2011; 105 2 385 386
74. Gosselin R. C., Adcock Funk D. M., Taylor J. M., et al. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban. Arch Pathol Lab Med: 2014; 138 12 1680 1684
75. Samama M. M., Contant G., Spiro T. E., et al. Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost: 2012; 107 2 379 387
76. Kubitza D., Becka M., Voith B., Zuehlsdorf M., Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther: 2005; 78 4 412 421
77. Samama M. M., Amiral J., Guinet C., Perzborn E., Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost: 2010; 104 5 1078 1079
78. Harenberg J., Krämer R., Giese C., Marx S., Weiss C., Wehling M. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis: 2011; 32 3 267 271
79. Mani H., Rohde G., Stratmann G., et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost: 2012; 108 1 191 198
80. Douxfils J., Tamigniau A., Chatelain B., et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost: 2013; 110 4 723 731
81. Adelmann D., Wiegele M., Wohlgemuth R. K., et al. Measuring the activity of apixaban and rivaroxaban with rotational thromboelastometry. Thromb Res: 2014; 134 4 918 923
82. Levi M., Moore K. T., Castillejos C. F., et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost: 2014; 12 9 1428 1436
83. Perzborn E., Heitmeier S., Laux V., Buchmüller A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res: 2014; 133 4 671 681
84. Casutt M., Konrad C., Schuepfer G. Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM™ Anaesthesist: 2012; 61 11 948 953
85. Bowry R., Fraser S., Archeval-Lao J. M., et al. Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke. Stroke: 2014; 45 3 880 883
86. Becker R. C., Alexander J. H., Newby L. K., et al. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost: 2010; 104 5 976 983
87. Yamahira N., Frost C., Fukase H., et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. Int J Clin Pharmacol Ther: 2014; 52 7 564 573
88. Douxfils J., Chatelain C., Chatelain B., Dogné J. M., Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost: 2013; 110 2 283 294
89. Gouin-Thibault I., Flaujac C., Delavenne X., et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost: 2014; 111 2 240 248
90. Hillarp A., Gustafsson K. M., Faxälv L., et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost: 2014; 12 9 1545 1553
91. Harenberg J., Du S., Weiss C., Krämer R., Hoppensteadt D., Walenga J.; working party: methods to determine apixaban of the Subcommittee on Control of Anticoagulation of the International Society of Thrombosis and Haemostasis. Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH. J Thromb Haemost: 2014; 12 5 801 804
92. Tripodi A., Padovan L., Testa S., et al. How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study. Clin Chem Lab Med: 2015; 53 2 265 273
93. Barrett Y. C., Wang Z., Knabb R. M. A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb Hemost: 2013; 19 5 522 528
94. Frost C., Nepal S., Wang J., et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol: 2013; 76 5 776 786
95. Upreti V. V., Wang J., Barrett Y. C., et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol: 2013; 76 6 908 916
96. Barrett Y. C., Wang Z., Frost C., Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost: 2010; 104 6 1263 1271
97. Becker R. C., Yang H., Barrett Y., et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis: 2011; 32 2 183 187
98. Frost C., Wang J., Nepal S., et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol: 2013; 75 2 476 487
99. Ogata K., Mendell-Harary J., Tachibana M., et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol: 2010; 50 7 743 753
100. Favaloro E. J., Plebani M., Lippi G. Regulation in hemostasis and thrombosis: part I-in vitro diagnostics. Semin Thromb Hemost: 2013; 39 3 235 249
101. Lippi G., Mattiuzzi C., Favaloro E. J. Thrombophilia testing in patients taking direct oral anticoagulants. Handle with care. Diagnosis: 2014; 1 4 311 312
102. Gómez-Outes A., Suárez-Gea M. L., Lecumberri R., Terleira-Fernandez A. I., Vargas-Castrillon E. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov: 2014; 9 1 2 10
103. Zahir H., Brown K. S., Vandell A. G., et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation: 2015; 131 1 82 90
104. Halim A. B., Samama M. M., Mendell J. Ex vivo reversal of the anticoagulant effects of edoxaban. Thromb Res: 2014; 134 4 909 913
105. Fukuda T., Honda Y., Kamisato C., Morishima Y., Shibano T. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost: 2012; 107 2 253 259
106. Dinkelaar J., Molenaar P. J., Ninivaggi M., de Laat B., Brinkman H. J., Leyte A. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban. J Thromb Haemost: 2013; 11 6 1111 1118
107. Solbeck S., Nilsson C. U., Engström M., Ostrowski S. R., Johansson P. I. Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study. Scand J Clin Lab Invest: 2014; 74 7 591 598
108. Körber M. K., Langer E., Ziemer S., Perzborn E., Gericke C., Heymann Cv. Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study. Clin Appl Thromb Hemost: 2014; 20 7 735 740
109. Eerenberg E. S., Kamphuisen P. W., Sijpkens M. K., Meijers J. C., Buller H. R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation: 2011; 124 14 1573 1579
110. Dinkelaar J., Patiwael S., Harenberg J., Leyte A., Brinkman H. J. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin Chem Lab Med: 2014; 52 11 1615 1623
111. Davis P. K., Musunuru H., Walsh M., Mitra R., Ploplis V., Castellino F. J. The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine. Thromb Haemost: 2012; 108 3 586 588
112. Marlu R., Hodaj E., Paris A., Albaladejo P., Cracowski J. L., Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost: 2012; 108 2 217 224
113. Di Minno A., Spadarella G., Prisco D., Franchini M., Lupoli R., Di Minno M. N. Clinical judgment when using coagulation tests during direct oral anticoagulant treatment: a concise review. Semin Thromb Hemost: 2013; 39 7 840 846
114. Favaloro E. J., Bonar R., Butler J., Marsden K. Laboratory testing for the new oral anticoagulants: a review of current practice. Pathology: 2013; 45 4 435 437
115. Harenberg J., Krämer S., Du S., Weiss C., Krämer R. Concept of a point of care test to detect new oral anticoagulants in urine samples. Thromb J: 2013; 11 1 15
116. Harenberg J., Du S., Krämer S., et al. Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples. Semin Thromb Hemost: 2013; 39 1 66 71
117. Harenberg J., Kraemer R. Measurement of the new anticoagulants. Thromb Res: 2012; 129 01 S106 S113
118. Harenberg J., Krämer S., Du S., et al. Measurement of rivaroxaban and apixaban in serum samples of patients. Eur J Clin Invest: 2014; 44 8 743 752
119. Harenberg J., Kraemer S., Du S., et al. Determination of direct oral anticoagulants from human serum samples. Semin Thromb Hemost: 2014; 40 1 129 134